LLY - Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement

2024-03-06 16:13:40 ET

Summary

• Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively.
• Company has potential to overcome other biologic drug companies targeting patients with inflammatory disorders by improving drug exposure by a significant margin.
• The global atopic dermatitis market is expected to reach $19.1 billion by 2030.
• APG808 is an IL-4Ra drug to soon be explored in a phase 1 study for the treatment of patients with chronic obstructive pulmonary disorder; Trial initiation expected in 1st half of 2024.

Apogee Therapeutics, Inc. ( APGE ) has reported positive results from its phase 1 study using its lead candidate APG777 for the treatment of patients with moderate-to-severe Atopic Dermatitis [AD] and other inflammatory disorders. The last time I went over this biotech, it had not yet reported this data. At the time, I believed that it could create a competitive edge over other IL-13 biologics based on half-life improvement. That is, how long drug exposure in the body lasts. I talked about this in my Seeking Alpha article entitled "Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing." In the article, I noted that such interim data from this phase 1 study was to be released. Not only did the company do so, but it was able to achieve a lot of positive outcomes....

For further details see: